News
Brachytherapy in early-stage breast cancer tumors is faster and with fewer side effects than conventional radiotherapy
These are the results of an international study with the participation of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL) and the Valencian Institute of Oncology (IVO) and in which they make a comparison between the two techniques.
Bellvitge Hospital, IDIBELL and Astrazeneca test an application that monitors heart failure using voice
Through a mobile device, HearO™ makes it possible to predict possible complications in patients with heart failure through speech, detect disease-related fluid accumulation and alert the doctor before hospitalization
New evidence for the correct detection of oropharyngeal cancers caused by the human papillomavirus
To establish whether oropharyngeal cancer was related to the human papillomavirus, the recomendation is do it through the p16 protein detection.
Now a study from IDIBELL published in The Lancet Oncology has shown that not all p16-positive oropharyngeal cancers are caused by the virus.
An investigation by HUB and IDIBELL shows the adaptation of bacteria in COPD patients and prolonged treatment with azithromycin
The IDIBELL Bacterial Epidemiology research group has published a paper on the adaptation of Haemophilus spp in patients with chronic obstructive pulmonary disease (COPD) and prolonged treatment with azithromycin.
Association between polyphenols from diet and body weight change
The results, published in Antioxidant and Obesity scientific journals, show that the intake of most polyphenols is associated with maintenance or a lower weight gain, highlighting those polyphenols present in fruits, vegetables, olive oil, tea, cocoa, or cereals integral.
Jut Against Cancer Association donates 6,000 euros to pancreatic cancer research
The Association Jut against cancer is a recently created association from Sant Boi de Llobregat that raises funds through different solidarity, sporting and creative initiatives in which the patients participate.
A drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers
The results of the TRITON3 study show that patients with prostate cancer treated with a PARP inhibitor, called Rucaparib, take almost twice as long for the disease to progress than those treated with conventional chemotherapy.
The Govern awards the Josep Trueta plaque for health merit to the Hospital de Bellvitge
The Govern approved today the awarding of the Josep Trueta medals and plaques to outstanding professionals and entities in the health field. Among the award-winning entities is the Bellvitge University Hospital, for its work as a reference center of maximum complexity for 2 million people. Likewise, one of the individual medals has been for Dr. Mònica Povedano, a neurologist at Hospital de Bellvitge and IDIBELL researcher.